Your browser doesn't support javascript.
loading
VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.
Fernández-Parejo, Natalia; Lorenzo-Martín, L Francisco; García-Pedrero, Juana M; Rodrigo, Juan P; Dosil, Mercedes; Bustelo, Xosé R.
Afiliação
  • Fernández-Parejo N; Centro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain.
  • Lorenzo-Martín LF; Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
  • García-Pedrero JM; Centro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain.
  • Rodrigo JP; Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
  • Dosil M; Laboratory of Stem Cell Bioengineering, École Polytechnique Fédérale de Lausanne, 1015, Lausanne, Switzerland.
  • Bustelo XR; Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
Sci Rep ; 14(1): 4060, 2024 02 19.
Article em En | MEDLINE | ID: mdl-38374399
ABSTRACT
VAV2 is an activator of RHO GTPases that promotes and maintains regenerative proliferation-like states in normal keratinocytes and oral squamous cell carcinoma (OSCC) cells. Here, we demonstrate that VAV2 also regulates ribosome biogenesis in those cells, a program associated with poor prognosis of human papilloma virus-negative (HPV-) OSCC patients. Mechanistically, VAV2 regulates this process in a catalysis-dependent manner using a conserved pathway comprising the RAC1 and RHOA GTPases, the PAK and ROCK family kinases, and the c-MYC and YAP/TAZ transcription factors. This pathway directly promotes RNA polymerase I activity and synthesis of 47S pre-rRNA precursors. This process is further consolidated by the upregulation of ribosome biogenesis factors and the acquisition of the YAP/TAZ-dependent undifferentiated cell state. Finally, we show that RNA polymerase I is a therapeutic Achilles' heel for both keratinocytes and OSCC patient-derived cells endowed with high VAV2 catalytic activity. Collectively, these findings highlight the therapeutic potential of modulating VAV2 and the ribosome biogenesis pathways in both preneoplastic and late progression stages of OSCC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / Proteínas Proto-Oncogênicas c-vav / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / Proteínas Proto-Oncogênicas c-vav / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2024 Tipo de documento: Article